Clinical Trials

Resmetirom is a THR-β agonist designed to target key underlying causes of MASH/NASH. Resmetirom has been investigated in several preclinical and clinical studies, with phase 3 trials currently underway.

Phase 3 Trials

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH)

A Phase 3 Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) Patients (MAESTRO-NAFLD-1)

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-Compensated NASH Cirrhosis (MAESTRO-NASH OUTCOMES)

Phase 2 Trials

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Resmetirom is currently only approved in the United States.